Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Ovid Therapeutics Inc. on June 6, 2024. The record date for the meeting was April 9, 2024, with 70,810,661 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 82.62% of outstanding shares (58,503,813 shares) were present, constituting a quorum. The following proposals were voted upon:
- Proposal 1 (Election of Directors): All nominees were elected to serve three-year terms until the 2027 annual meeting.
- Barbara Duncan: 36,686,822 votes For; 5,581,389 votes Withheld.
- Robert Michael Poole: 40,158,684 votes For; 2,109,527 votes Withheld.
- Proposal 2 (Advisory Executive Compensation): Approved on an advisory basis.
- For: 40,499,565 votes
- Against: 1,760,461 votes
- Abstain: 8,185 votes
- Proposal 3 (Ratification of Auditors): Ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 57,201,432 votes
- Against: 1,293,006 votes
- Abstain: 9,375 votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the full list of director nominees and their biographies in the definitive proxy statement filed on April 24, 2024.
- Confirm the specific compensation details for named executive officers referenced in Proposal 2.
- Review the engagement letter or audit scope with KPMG LLP for the 2024 fiscal year.
- Note the significant number of broker non-votes (16,235,602) on director elections, indicating shares held in street name where brokers lacked discretionary voting power.